Journal: Materials Today Bio

Article Title: Y-shaped trivalent aptamer for targeted visualization and tracking of reprogrammed astrocytes

doi: 10.1016/j.mtbio.2025.102482

Figure Lengend Snippet: Specific binding and quantification of dye–labeled aptamers in U87MG (human astrocytic glioblastoma) and C6 (rat glial glioblastoma) cells. (A, B) Representative FL images of U87MG and C6 cells treated with Alexa488–labeled ΔAst17-30 (200 nM) or Tri-ΔAst17-30 (66 nM) aptamers, showing BF, Alexa488 (green), DAPI (blue), and merged channels. Scale bars, 100 μm. (C) Box plots of MFI values of the two aptamers showing significant differences in aptamer binding between U87MG and C6 cells ( p < 0.0001 for both ΔAst17-30 and Tri-ΔAst17-30, N = 12), as well as significant difference in binding strength between the two aptamers in U87MG cells ( p < 0.0001, N = 12). (D) Flow cytometry quantifies Alexa488–positive U87MG and C6 cells after Tri-ΔAst17-30 treatment (final 66 nM), revealing specific aptamer binding in U87MG but not C6 cells. The square gates define the percentage of aptamer-positive cells within the total population, which was 92.9 % for U87MG and 4.73 % for C6, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Human astrocytic glioblastoma U-87MG and rat glial glioblastoma C6 cell lines were acquired form the Korean Cell Line Bank (Seoul, Korea).

Techniques: Binding Assay, Labeling, Flow Cytometry